Article
Antitumoral activity of tyrosine kinase inhibitors in patients with non-small cell lung cancer harbouring rare epidermal growth factor receptor mutations.
Molecular diagnosis & therapy - 1 Oct 2015
Oyaert Matthijs, Demedts Ingel, Boone Elke, Dedeurwaerdere Franceska, Vandorpe Jo, De Laere Emmanuel, Breyne Joke
Abstract excerpt
INTRODUCTION: Mutations in the epidermal growth factor receptor (EGFR) have been reported as predictive markers of tumour response to tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancer (NSCLC). Although the "common" EGFR mutations have been associated with response to EGFR-TKIs, the correlation with response to treatment for many other rare mutations is still unclear. The aim of this...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.